Oncology Central

Predicting the chance of relapse after tamoxifen treatment in breast cancer


Breast cancer treatment emerged as the model for tailored therapy with the introduction of antihormonal modalities and the measurement of estrogen receptors as a clinically applicable biomarker [1]. In the adjuvant setting tamoxifen treatment is administered to reduce the risk of recurrence and death in estrogen receptor (ER)-positive breast cancer [2]. It has been confirmed by multiple clinical trials that ER-negative tumors almost entirely fail to respond to antihormonal agents [3,4]

To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.